Work

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials

Year: 2015

Type: review

Source: The Lancet

DOI: 10.1016/s0140-6736(14)61730-x

Authors: Jessica L Mega, Nathan O Stitziel, J Gustav Smith, Daniel I Chasman, Mark J Caulfield, James J Devlin, Francesco Nordio, Craig L Hyde, Christopher P Cannon, Frank M Sacks, Neil R Poulter, Peter S Sever, Paul M Ridker, Eugene Braunwald, Olle Melander, Sekar Kathiresan, Marc S Sabatine

Institutions: Brigham and Women's Hospital, Harvard University, Thrombolysis in Myocardial Infarction Study Group, Washington University in St. Louis, Broad Institute, Lund University, Massachusetts General Hospital, Skåne University Hospital, Massachusetts Institute of Technology, Queen Mary University of London, William Harvey Research Institute, Quest Diagnostics (United States), Pfizer (United States), Imperial College London

Language: English

Topic: Lipoproteins and Cardiovascular Health

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institute for Health and Care Research, Novo Nordisk Fonden, Medical Research Council, National Heart, Lung, and Blood Institute

Awards: Using genetic variation to study biology of blood lipids & coronary heart disease, Rare coding variation and risk for myocardial infarction, G2107972360, G3803372573, NIHR Senior Investigator Award, NIHR Senior Investigator Award, G5384371102, Antiplatelet Therapy: Platelet Inhibition, Polymorphisms, and Protein Biomarkers, Genetic Risk Stratification to Identify Individuals for Early Statin Therapy, NIHR Senior Investigator Award

OpenAlex ID: W2171705978

FWCI: 12.55

Cites: 46

Cited by: 704

Related to: 10